 european experi itraconazol system mycos januari patient deep fungal infect itraconazol mg/day northern itali evalu drug efficaci toler possibl patient sporotrichosi aspergillosi cryptococcosi mainli patient posit human immunodefici viru respons case sporotrichosi patient differ form aspergillosi patient invas pulmonari aspergillosi patient cryptococcosi itraconazol activ infect and/or prevent relaps activ infect itraconazol patient itraconazol flucytosin patient patient itraconazol mainten therapi month relaps relaps declin serum antigen serum antigen titer except hypokalemia patient itraconazol patient drug sever month year